がん診断の市場規模、シェア、成長分析、製品別、技術別、用途別、エンドユーザー別、地域別 - 産業予測 2025-2032年

がん診断の市場規模は2023年に1,100億米ドルと評価され、2024年の1,196億8,000万米ドルから2032年には2,349億9,000万米ドルに成長し、予測期間（2025-2032年）のCAGRは8.8%で成長する見通しです。

世界のがん罹患数の増加により、がん診断の需要は今後数年間で大幅に拡大するとみられます。市場成長の主な促進要因としては、腫瘍学調査への多額の投資や、治療成績の改善につながるがんの早期発見への注目の高まりが挙げられます。さらに、さまざまながん種に対する意識の高まりや診断技術の革新が需要をさらに押し上げると予想されます。また、標的療法や個別化医療へのシフトも、高度な診断ツールの使用を促進すると思われます。しかし、高コスト、偽陽性のリスク、アクセス制限などの課題は、この期間およびそれ以降を通じて市場の可能性を制限する可能性があります。全体として、がん診断市場は、このようなダイナミクスが進化する中で、大幅な成長を遂げようとしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 特許分析
• 規制分析
• 技術分析
• ケーススタディ

がん診断市場規模：製品別& CAGR（2025-2032）

• 市場概要
• 消耗品
  • 抗体
  • キットと試薬
  • プローブ
  • その他の消耗品
• 機器
  • 病理学ベースの機器
  • スライド染色システム
  • 組織処理システム
  • Cellプロセッサ
  • PCR機器
  • NGS機器
  • マイクロアレイ
  • その他の病理学ベースの機器
  • 画像機器
  • CTシステム
  • 超音波システム
  • MRIシステム
  • マンモグラフィーシステム
  • 核イメージングシステム
  • 生検器具

がん診断市場規模：技術別& CAGR（2025-2032）

• 市場概要
• 体外診断検査
  • ポリメラーゼ連鎖反応
  • インサイチューハイブリダイゼーション
  • 免疫組織化学
  • 次世代シーケンシング
  • 免疫測定
  • マイクロアレイ
  • フローサイトメトリー
  • その他のIVD技術
• イメージングテクノロジー
  • 磁気共鳴画像法
  • コンピュータ断層撮影
  • 核イメージング
  • マンモグラフィー
  • 超音波
• 生検

がん診断市場規模：用途別& CAGR（2025-2032）

• 市場概要
• 乳がん
• 肺がん
• 大腸がん
• 黒色腫
• その他のがん

がん診断市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• 診断検査室

がん診断市場規模& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024年）

主要企業プロファイル

• Abbott Laboratories（US）
• Becton, Dickinson and Company（BD）（US）
• bioMerieux SA（France）
• Danaher Corporation（US）
• Hoffmann-La Roche Ltd.（Switzerland）
• GE Healthcare（US）
• Hologic, Inc.（US）
• Illumina, Inc.（US）
• Koninklijke Philips N.V.（Netherlands）
• Merck KGaA（Germany）
• Myriad Genetics, Inc.（US）
• QIAGEN N.V.（Netherlands）
• Siemens Healthineers AG（Germany）
• Sysmex Corporation（Japan）
• Thermo Fisher Scientific Inc.（US）
• Exact Sciences Corporation（US）
• Guardant Health, Inc.（US）
• Caris Life Sciences（US）

結論と提言

Cancer Diagnostics Market size was valued at USD 110.0 billion in 2023 and is poised to grow from USD 119.68 billion in 2024 to USD 234.99 billion by 2032, growing at a CAGR of 8.8% during the forecast period (2025-2032).

The global rise in cancer incidences is set to significantly enhance the demand for cancer diagnostics in the coming years. Key drivers for market growth include substantial investments in oncology research and an increasing focus on early cancer detection, which can lead to improved treatment outcomes. Additionally, heightened awareness of various cancer types and innovations in diagnostic technologies are expected to further boost demand. The shift towards targeted therapies and personalized medicine will also propel the use of advanced diagnostic tools. However, challenges such as high costs, the risk of false positives, and restricted access may limit market potential throughout this period and beyond. Overall, the cancer diagnostics market is poised for substantial growth amidst these evolving dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cancer Diagnostics Market Segments Analysis

Global Cancer Diagnostics Market is segmented by Product, Technology, Application, End User and region. Based on Product, the market is segmented into Consumables and Instruments. Based on Technology, the market is segmented into IVD Testing, Imaging Technologies and Biopsies. Based on Application, the market is segmented into Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma and Other Cancers. Based on End User, the market is segmented into Hospitals and Diagnostic Laboratories. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cancer Diagnostics Market

The rising prevalence of cancer has become a pressing issue globally, largely driven by poor lifestyle choices and the widespread adoption of unhealthy habits. This increase in cancer incidence is a major catalyst for the growing demand for cancer diagnostics. As more individuals are diagnosed with various types of cancer, there is an urgent need for effective diagnostic tools and services to support early detection and treatment. Consequently, the cancer diagnostics market is experiencing significant growth, addressing the critical need for timely and accurate diagnosis, thus ultimately improving patient outcomes and advancing healthcare solutions in this vital area.

Restraints in the Cancer Diagnostics Market

The Cancer Diagnostics market faces significant restraints, particularly in underdeveloped and developing nations that are still striving to enhance their healthcare infrastructure. In these regions, healthcare facilities often operate with constrained budgets, limiting their ability to invest in advanced diagnostic technologies. As a result, access to innovative diagnostic procedures is significantly hampered, hindering the identification and treatment of cancer. This lack of financial resources restricts the adoption of state-of-the-art diagnostic devices, ultimately impacting the overall effectiveness and progression of cancer diagnosis in these markets. Consequently, this limitation poses a notable challenge to the growth of the Cancer Diagnostics industry globally.

Market Trends of the Cancer Diagnostics Market

The Cancer Diagnostics market is witnessing a significant trend toward the integration of artificial intelligence (AI) technologies, poised to revolutionize traditional diagnostic methods. Companies are increasingly leveraging AI in diagnostic imaging, enhancing accuracy and efficiency in identifying malignancies at earlier stages. This innovation not only streamlines the diagnostic process but also presents new business opportunities for companies specializing in cancer detection. By harnessing the power of AI, firms can improve patient outcomes, reduce diagnostic errors, and optimize resource allocation. As the demand for precise and rapid cancer diagnostics grows, the successful adoption of AI will be a critical differentiator in a competitive landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Patent Analysis
• Regulatory Analysis
• Technology Analysis
• Case Studies

Global Cancer Diagnostics Market Size by Product & CAGR (2025-2032)

• Market Overview
• Consumables
  • Antibodies
  • Kits & Reagents
  • Probes
  • Other Consumables
• Instruments
  • Pathology-Based Instruments
  • Slide staining systems
  • Tissue processing systems
  • Cell processors
  • PCR instruments
  • NGS instruments
  • Microarrays
  • Other pathology-based instruments
  • Imaging Instruments
  • CT systems
  • Ultrasound systems
  • MRI systems
  • Mammography systems
  • Nuclear imaging systems
  • Biopsy Instruments

Global Cancer Diagnostics Market Size by Technology & CAGR (2025-2032)

• Market Overview
• IVD Testing
  • Polymerase Chain Reaction
  • In Situ Hybridization
  • Immunohistochemistry
  • Next-Generation Sequencing
  • Immunoassay
  • Microarray
  • Flow Cytometry
  • Other IVD Technologies
• Imaging Technologies
  • Magnetic Resonance Imaging
  • Computed Tomography
  • Nuclear Imaging
  • Mammography
  • Ultrasound
• Biopsies

Global Cancer Diagnostics Market Size by Application & CAGR (2025-2032)

• Market Overview
• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Other Cancers

Global Cancer Diagnostics Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Diagnostic Laboratories

Global Cancer Diagnostics Market Size & CAGR (2025-2032)

• North America (Product, Technology, Application, End User)
  • US
  • Canada
• Europe (Product, Technology, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caris Life Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations